Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

Also called NCT05528419

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 320 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05528419
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05528419. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (actual); primary completion 2026-01-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
Condition
Atrial Fibrillation Recurrent
Condition
Hypertension
Intervention (Drug)
Sacubitril-valsartan
Intervention (Drug)
Valsartan
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct05528419
Content hash
79aea747b156ff9e0c993bc1556e1aab16265912eef7a86a14aa368fe6415662